Objective: In order to investigate the possible association between mast cells (MCs) and the fibrous plaque of La Peyronie’s disease, the number of MCs in normal penile tissue and in the fibrous plaque was determined.Methods: The control group consisted of 5 total and 3 partial penectomies with no fibrotic lesions, while the study group consisted of 23 excisional biopsies from cases of La Peyronie’s disease dating back to at least 2 years earlier and with no signs of activity. The biopsies included tissues from the tunica albuginea (TA), the areolar tissue (Br) between the tunica and the erectile tissue (CC) and from the latter. The number of MCs was counted with the aid of an image analysis program following staining the antibody antitryptase.Results: In the cases of La Peyronie’s disease the number of MCs/mm2 was significantly higher in the TA and Br but lower in the CC. The MCs were related to fibroblasts and vasculonervous channels in the TA, and were concentrated around the fibrous plaques and granulation tissue between the TA and BR and between the latter and the CC.Conclusion: Our data indicate that MCs have a role in the genesis of the fibrous plaque in the TA and in the persistent inflammation in the Br. Medical treatment aimed at repressing MC activation and proliferation locally might be useful in La Peyronie’s disease.

Keywords:
Mast cells, Tryptase, La Peyronie, Penis, Fibrosis, Immunohistochemistry
1.
Devine CJ Jr: International conference on Peyronie’s disease. Introduction. J Urol 1997;157: 272–275.
2.
Brock G, Hsu GL, Nunes L, von Heyden B, Lue TF: The anatomy of the tunica albuginea in the normal penis and Peyronie’s disease. J Urol 1997;157:276–281.
3.
Gentile V, Modesti A, La Pera G, Vasaturo F, Modica A, Prigiotti GE, Di Silverio F, Scarpa S: Ultrastructural and immunohistochemical characterization of the tunica albuginea in Peyronie’s disease and veno–occlusive dysfunction. J Androl 1996;17:96–103.
4.
Akkus E, Carrier S, Baba K, Hsu GL, Padma–Nathan H, Nunes L, Lue TF: Structural alterations in the tunica albuginea of the penis: Impact of Peyronie’s disease, ageing and impotence. Br J Urol 1997;79:47–53.
5.
Iacono F, Barra S, De Rosa G, Boscaino A, Lotti T: Microstructural disorder of tunica albuginea in patients affected by Peyronie’s disease with or without erection dysfunction. J Urol 1993;150:1806–1809.
6.
Weidner W, Schroeder–Printzen I, Weiske WH, Vosshenrich R: Sexual dysfunction in Peyronie’s disease: An analysis of 222 patients without previous local plaque therapy. J Urol 1997;157:325–328.
7.
Leffel MS: Is there an immunogenetic basis for Peyronie’s disease? J Urol 1997;157:295–297.
8.
Devine CJ Jr, Somers KD, Jordan GH, Schlossberg SM: Proposal: Trauma as the cause of the Peyronie’s lesion. J Urol 1997; 157:285–290.
9.
Van de Water L: Mechanisms by which fibrin and fibronectin appear in healing wounds: Implications for Peyronie’s disease. J Urol 1997; 157:306–310.
10.
Somers KD, Dawson DM: Fibrin deposition in Peyronie’s disease plaque. J Urol 1997;157: 311–315.
11.
Jarow PJ, Lowe, FC: Penile trauma: An etiologic factor in Peyronie’s disease and erectile dysfunction. J Urol 1997;158:1388–1390.
12.
Ralph DJ, Mirakian R, Pryor JP, Bottazzo GF: The immunological features of Peyronie’s disease. J Urol 1996;155:159–162.
13.
Nachtsheim DA, Rearden A: Peyronie’s disease is associated with an HLA class II antigen, HLA–DQ5, implying an autoimmune etiology. J Urol 1996;156:1330–1334.
14.
Ralph DJ, Schwartz G, Moore W, Pryor JP, Ebringer A, Bottazzo GF: The genetic and bacteriological aspects of Peyronie’s disease. J Urol 1997;157:291–294.
15.
Davies C: The microscopic pathology of Peyronie’s disease. J Urol 1997;157:282–284.
16.
Ehrlich HP: Scar contracture: Cellular and connective tissue aspects in Peyronie’s disease. J Urol 1997;157:316–319.
17.
Wahl SM: Inflammation and growth factors. J Urol 1997;157:303–305.
18.
Diegelmann RF: Cellular and biochemical aspects of normal and abnormal wound healing: An overview. J Urol 1997;157:298–302.
19.
El–Sakka AI, Hassoba HM, Pillarisetty RJ, Dahiya R, Lue TF: Peyronie’s disease is associated with an increase in transforming growth factorB protein expression. J Urol 1997;158: 1391–1394.
20.
El–Sakka AI, Hassoba HM, Chui RM, Bhatnagar RS, Dahiya RD, Lue TF: An animal model of Peyronie’s–like condition associated with an increase of transforming growth factor–beta mRNA and protein expression. J Urol 1997; 158:2284–2290.
21.
Galli SJ: New concepts about mast cell. N Engl J Med 1993;328:257–265.
22.
Galli SJ: Biology of disease. New insights into ‘the riddle of the mast cells’: Microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest 1990;62:5–33.
23.
Valent P: The riddle of the mast cell:kit (CD117)–ligand as the missing link? Immunol Today 1994;15:111–114.
24.
Claman HN: On scleroderma. Mast cells, endothelial cells and fibroblasts. JAMA 1989; 262:1206–1209.
25.
Heard BE, Dewar A, Corrin B: Apposition of fibroblasts to mast cells and lymphocytes in normal human lung and in croptogenic fibrosing alveolitis. Ultrastructure and cell perimeter measurements. J Pathol 1992;303–312.
26.
Inoue Y, King TE, Jr, Tinkle SS, Dockstader K, Newman LS: Human mast cell basic fibroblast growth factor in pulmonary fibrotic disorders. Am J Pathol 1996;149:2037–2054.
27.
Schubert G: IPP: Morfopatologia; in Pisani E, Mantovani F (eds): Simposio internazionale sull’ Induratio Penis Plastica. Milan, Masson, 1985, pp 3–17.
28.
Fontana D, Rolle L, Lacivita A, Mattiello L, Del Noce G, Tamagnone A: Mast cells e induratio penis plastica; in Malattia di La Peyronie. Artur, 1994, p 40.
29.
Fontana D, Rolle L, Tamagnone A, Mattiello L, Ragnie F, Ceruti C, Gani F: Etiopathogenesis of induratio penis plastica: Possible role of mast cells. Acta Urol Ital 1998;12:161–163.
30.
Irani AMA, Bradford TR, Kepley CL, Schechter NM, Schwartz LB: Detection of MCt and MCtc types of human mast cells by immunohistochemistry using new monoclonal antitryptase and anti–chymase antibodies. J Histochem Cytochem 1989;37:1509–1515.
31.
Walls AF, Brain SD, Desai A, Jose PJ, Hawkings E, Church MK, Williams TJ: Human mast cell tryptase attenuates the vasodilator activity of calcitonin gene–related peptide. Biochem Pharmacol 1992;43:1243–1248.
32.
Li VW, Kapadia SB, Sommez–Alpan E, Swerdlow SH: Immunohistochemical characterization of mast cell disease in paraffin sections using tryptase. CD68, myeloperoxidase, lysozyme, and CD20 antibodies. Mod Pathol 1996;9:982–988.
33.
Smith BH: Subclinical Peyronie’s disease. Am J Clin Pathol 1969;52:385–390.
34.
Gingell JC, Desai KM: Peyronie disease. Br J Urol 1989;63:223–226.
35.
Gelbard MK, Dorey F, James K: The natural history of Peyronie disease. J Urol 1990;144: 1376–1379.
36.
Dunsmuir WD, Kirby RS: Historical review. François de La Peyronie (1678–1747): The man and the disease he described. Br J Urol 1996;78:613–622.
37.
Jeziorska M, Collum C, Wooley DE: Mast cell distribution, activation and phenotype in atherosclerosic lesions of human carotid arteries. J Pathol 1997;182:115–122.
38.
Bonetti F, Pea M, Martignoni G, Zamboni G, Manfrin E, Colombari R, Mariuzzi GM: The perivascular epithelioid cell and related lesions. Adv Anat Pathol 1997;6:343–358.
39.
Ruoss SJ, Hartmann T, Caughey GH: Mast cell tryptase is a mitogen for cultured fibroblasts. J Clin Invest 1991;88:493–499.
40.
Gordon JR, Galli SJ: Promotion of mouse fibroblast collagen gene expression by mast cells stimulated via the FCeRI. Role for mast cell–derived transforming growth factor–b and tumor necrosis factor–α. J Exp Med 1994;180: 2027–2037.
41.
Nukkarinen A, Jarvikallo A, Lakkakorpi J, Harvima IT, Harvima RJ, Horsmanheimo M: Quantitative histochemical analysis of mast cells and sensory nerves in psoriatic skin. J Pathol 1996;180:200–205.
42.
Levi–Schaffer F, Rubinchik E: Mast cell role in fibrotic disease. Isr J Med Sci 1995;31:450– 453.
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.